" class="no-js "lang="en-US"> ResApp Health Limited - Medtech Alert
Thursday, November 30, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
ResApp Health | Pharmtech Focus

ResApp Health Limited

About ResApp Health Limited

ResApp Health Limited

ResApp is developing digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease. We are creating easy to use, affordable, clinically-validated and regulatory-cleared diagnostic tools that only require a smartphone. Our solutions are designed to be easily integrated into existing telehealth solutions and we are also working on apps to provide respiratory disease diagnosis and management directly to consumers and healthcare providers.

ResApp was founded in September 2014 to commercialise technology developed by Associate Professor Udantha Abeyratne that uses sound to diagnose respiratory disease. Associate Professor Abeyratne’s team has been engaged in the research and development of this technology since 2009 and has been funded by the Bill and Melinda Gates Foundation, The University of Queensland and UniQuest. ResApp listed on the Australian Stock Exchange in July 2015 and was named “Australian Emerging Company of the Year” at the Johnson & Johnson Innovation 2016 Industry Excellence Awards.

Related Story

COVID-19

 Detecting Covid-19 Using Only a Smartphone | Pharmtech Focus

Detecting Covid-19 Using Only a Smartphone

March 22 2022

ResApp Health Limited (ASX:RAP) today announced positive results for a new novel cough audio-based COVID-19 […]